Neurocrine

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Neurocrine and other ETFs, options, and stocks.

About NBIX

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. 

CEO
Kyle W. Gano
CEOKyle W. Gano
Employees
1,800
Employees1,800
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1992
Founded1992
Employees
1,800
Employees1,800

NBIX Key Statistics

Market cap
13.20B
Market cap13.20B
Price-Earnings ratio
31.62
Price-Earnings ratio31.62
Dividend yield
Dividend yield
Average volume
1.31M
Average volume1.31M
High today
$134.02
High today$134.02
Low today
$131.36
Low today$131.36
Open price
$133.26
Open price$133.26
Volume
1.01M
Volume1.01M
52 Week high
$160.18
52 Week high$160.18
52 Week low
$84.23
52 Week low$84.23

Stock Snapshot

As of today, Neurocrine(NBIX) shares are valued at $132.39. The company's market cap stands at 13.2B, with a P/E ratio of 31.62.

During the trading session on 2026-01-18, Neurocrine(NBIX) shares reached a daily high of $134.02 and a low of $131.36. At a current price of $132.39, the stock is +0.8% higher than the low and still -1.2% under the high.

Trading volume for Neurocrine(NBIX) stock has reached 1.01M, versus its average volume of 1.31M.

The stock's 52-week range extends from a low of $84.23 to a high of $160.18.

The stock's 52-week range extends from a low of $84.23 to a high of $160.18.

NBIX News

Simply Wall St 2d
A Look At Neurocrine Biosciences Valuation After New INGREZZA Head To Head Clinical Data

Advertisement Clinical data and why it matters for Neurocrine Biosciences (NBIX) Neurocrine Biosciences (NBIX) put fresh clinical data for INGREZZA in front o...

A Look At Neurocrine Biosciences Valuation After New INGREZZA Head To Head Clinical Data
TipRanks 3d
Neurocrine’s Ingrezza capsules show efficacy in involuntary movement disorders

Neurocrine (NBIX) announced the presentation of the first head-to-head data comparing vesicular monoamine transporter 2, or VMAT2, target occupancy between Ingr...

Nasdaq 5d
NBIX Crosses Below Key Moving Average Level

In trading on Thursday, shares of Neurocrine Biosciences, Inc. (Symbol: NBIX) crossed below their 200 day moving average of $90.02, changing hands as low as $88...

NBIX Crosses Below Key Moving Average Level

Analyst ratings

87%

of 30 ratings
Buy
86.7%
Hold
13.3%
Sell
0%

People also own

Based on the portfolios of people who own NBIX. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the .